主 办:北 京 中 医 药 大 学
ISSN 1006-2157 CN 11-3574/R

JOURNAL OF BEIJIGN UNIVERSITY OF TRADITIONAL CHINE ›› 2016, Vol. 39 ›› Issue (9): 779-782.doi: 10.3969/j.issn.1006-2157.2016.09.016

Previous Articles     Next Articles

Clinical efficacy of Yiqi Yangyin xiaozheng Tongluo Fang on patients with stage IV diabetic nephropathy*

GUO Qian1, CHEN Zhiqiang2#, FANG Jing1, BAI Lu1,WANG Yuehua3, GUO Dengzhou2, WANG Yuansong4, ZHOU Chao5, ZHANG Jianghua1   

  1. 1 Hebei Medical University, Hebei 050017;
    2 Hebei Traditional Chinese Medicine Hospital;
    3 The Third Hospital of Hebei Medical University;
    4 Hebei Province Cangzhou Hospital Integrated Traditional and Western Medicine;
    5 Hebei Province Qinhuangdao Traditional Chinese Medicine Hospital
  • Received:2016-04-12 Online:2016-09-30 Published:2016-09-30

Abstract: Objective To investigate the clinical efficacy of Yiqi Yangyin xiaozheng Tongluo Fang (YYXTF), a Chinese medicine compounds formulated by the principle of replenishing qi, nourishing yin, eliminating abdominal masses, and freeing the collateral vessels, on patients with stage IV diabetic nephropathy (DN). Methods A total of 160 patients with stage IV diabetic nephropathy according to inclusion criteria were randomly divided into traditional Chinese medicine group (TCM group, n=81) and control group (n=79). In addition to general treatment, patients in TCM group took orally YYHXF and those in control group took irbesartan for consecutive six months. The incidence of end point events, improvement of clinical symptoms and urine micro-albumin excretion rate (mAlb), 24 hours urine total protein (U-pro/24 h), serum creatinine (Scr), blood urea nitrogen (BUN), fasting plasma glucose (FPG), glycosylated hemoglobin (HbAlc), total cholesterol (TC) and triglycerides (TG) were recorded before and after treatment. Results During the follow-up period, compared with control group whose two patients with Scr >133 μmol/L, TCM group without patients progressing to stage V showed no statistical significance (P>0.05). Efficacy rate of relieving symptoms of hypodynamia, mouth dryness, back pain, edema in TCM group were significantly higher than that of control group (P<0.01). Intragroup comparison showed that mAlb and U-pro/24 h decreased after treatment (P<0.01). After treatment, mAlb and U-pro/24 h of TCM group were significantly lower than that of control group (P<0.05), and the level of TG of TCM group also decreased(P<0.05) . Conclusion Yiqi Yangyin Huayu Tongluo Fang showed definite therapeutic effect on stage IV diabetic nephropathy proteinuria. It could reduce TG levels and protected against dyslipidemia. In addition, it relieved the symptoms and improved the quality of patients’ life.

Key words: Yiqi Yangyin Xiaozheng Tongluo Fang, diabetic nephropathy, clinical trial, irbesartan

CLC Number: 

  • R225.4